Cochrane · systematic review · CD011006
Antidepressants for the treatment of depression in people with cancer
Vita, G, Compri, B, Matcham, F, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
9
current version
GRADE rated
9
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 9 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 3 versionsAntidepressants compared to placebo for people with cancer and depression
Population: adults with cancer and depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Efficacy as a continuous outcome Antidepressants vs placebo | no estimate extracted | 7 studies · 511 participants | Very low Downgraded: risk of bias, inconsistency |
Efficacy as a dichotomous outcome Antidepressants vs placebo | RR 0.74 [0.57, 0.96] | 7 studies · 662 participants | Very low Downgraded: risk of bias, inconsistency |
Dropouts due to any cause (acceptability) Antidepressants vs placebo | RR 0.85 [0.52, 1.38] | 9 studies · 479 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Selective serotonin reuptake inhibitors (SSRIs) compared to tricyclic antidepressants (TCAs) for people with cancer and depression
Population: people with cancer and depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Efficacy as a continuous outcome Selective serotonin reuptake inhibitors (SSRIs) vs tricyclic antidepressants (TCAs) | no estimate extracted | 3 studies · 237 participants | Very low Downgraded: risk of bias, imprecision |
Efficacy as a dichotomous outcome Selective serotonin reuptake inhibitors (SSRIs) vs tricyclic antidepressants (TCAs) | RR 1.1 | 2 studies · 199 participants | Very low Downgraded: risk of bias, imprecision |
Dropouts due to any cause (acceptability) Selective serotonin reuptake inhibitors (SSRIs) vs tricyclic antidepressants (TCAs) | RR 0.83 [0.53, 1.3] | 3 studies · 237 participants | Very low Downgraded: risk of bias, imprecision |
Mirtazapine compared to tricyclic antidepressants (TCA) for people with cancer and depression
Population: adults with cancer and depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Efficacy as a continuous outcome Mirtazapine vs tricyclic antidepressants (TCA) | no estimate extracted | 1 study · 25 participants | Very low Downgraded: risk of bias, imprecision |
Efficacy as a dichotomous outcome Mirtazapine vs tricyclic antidepressants (TCA) | RR 0.81 [0.6, 1.09] | 1 study · 33 participants | Very low Downgraded: risk of bias, imprecision |
Dropouts due to any cause (acceptability) Mirtazapine vs tricyclic antidepressants (TCA) | RR 0.65 [0.2, 2.15] | 1 study · 33 participants | Very low Downgraded: risk of bias, imprecision |